Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma.
We report the results of treatment with MACOP-B in 11 young patients with low grade lymphoma (LGL). Complete remission was obtained in 4 (57%) and partial remission in 3 (42.8%) of 7 evaluable patients. However, this aggressive chemotherapy has not offered any advantage because of an unacceptably high treatment-related morbidity and mortality (17%). Serious infection during neutropenia was the most common complication.
Arranz
R
R
Servicio de Hematologia, Hospital de la Princesa, Madrid, Spain.
Pérez
G
G
Steegmann
J L
JL
Cámara
R
R
Tomás
J F
JF
Figuera
A
A
Vazquez
L
L
Fernández-Rañada
J M
JM
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006098:Granulocytes / Q000187:drug effects; D006801:Humans; D007239:Infections / Q000209:etiology; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D016019:Survival Analysis; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate